J 2018

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

HÁJEK, Roman, Jiří JARKOVSKÝ, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA et. al.

Základní údaje

Originální název

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Autoři

HÁJEK, Roman (203 Česká republika, garant), Jiří JARKOVSKÝ (203 Česká republika, domácí), Vladimír MAISNAR (203 Česká republika), Luděk POUR (203 Česká republika, domácí), Ivan ŠPIČKA (203 Česká republika), Jiří MINAŘÍK (203 Česká republika), Evžen GREGORA (203 Česká republika), Petr KESSLER (203 Česká republika), Michal SÝKORA, Hana FRAŇKOVÁ (203 Česká republika), Marco CAMPIONI (756 Švýcarsko), Lucy DECOSTA (826 Velká Británie a Severní Irsko), Maarten TREUR (528 Nizozemské království), Sebastian GONZALEZ-MCQUIRE (756 Švýcarsko) a Walter BOUWMEESTER (528 Nizozemské království)

Vydání

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, DALLAS, CIG MEDIA GROUP, LP, 2018, 2152-2650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.274

Kód RIV

RIV/00216224:14110/18:00104655

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000432995800001

Klíčová slova anglicky

Czech Republic; MM; RMG; Survival; Treatment patterns

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 2. 2019 18:34, Soňa Böhmová

Anotace

V originále

The Registry of Monoclonal Gammopathies (RMG) collects long-term data for patients with hematologic malignancies and is one of the largest registries of its type in Europe. The present noninterventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into the real-world treatment outcomes of patients with multiple myeloma. Introduction: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. Materials and Methods: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. Results: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (<= 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. Conclusion: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.